Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Ruilope

Showing results (1-10 of 284) with videos related to

Pageof 29
Sort By:
Acta Diabetologica|May 4, 2005
Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?L M Ruilope
American Journal of Hypertension|June 20, 2001
Kidney dysfunction: a sensitive predictor of cardiovascular riskL M Ruilope
Journal of Human Hypertension|July 1, 1995
The hidden truth: what do the clinical trials really tell us about BP control?L M Ruilope
American Journal of Hypertension|January 23, 1998
Renoprotection and renin-angiotensin system blockade in diabetes mellitusL M Ruilope
Advances in Therapy|July 12, 2001
Valsartan and the kidney: review of preclinical and clinical dataL M Ruilope
Medicina Clinica|October 19, 1991
[The usefulness of postsynaptic alpha blockaders in treating arterial hypertension]L M Ruilope
International Journal of Clinical Practice|May 1, 2004
What is the impact of PRIME on real-life diabetic nephropathy?L M Ruilope
International Journal of Clinical Practice. Supplement|June 28, 2005
AT1-receptor blockers and ACE inhibitors: alternatives or partners?L M Ruilope
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 1, 1997
The kidney and cardiovascular riskL M Ruilope
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 1, 1995
Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathyL M Ruilope
Pageof 29

Showing results (1-10 of 284) with videos related to

Sort By:
Pageof 29
Acta Diabetologica|May 4, 2005
Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?L M Ruilope
American Journal of Hypertension|June 20, 2001
Kidney dysfunction: a sensitive predictor of cardiovascular riskL M Ruilope
Journal of Human Hypertension|July 1, 1995
The hidden truth: what do the clinical trials really tell us about BP control?L M Ruilope
American Journal of Hypertension|January 23, 1998
Renoprotection and renin-angiotensin system blockade in diabetes mellitusL M Ruilope
Advances in Therapy|July 12, 2001
Valsartan and the kidney: review of preclinical and clinical dataL M Ruilope
Medicina Clinica|October 19, 1991
[The usefulness of postsynaptic alpha blockaders in treating arterial hypertension]L M Ruilope
International Journal of Clinical Practice|May 1, 2004
What is the impact of PRIME on real-life diabetic nephropathy?L M Ruilope
International Journal of Clinical Practice. Supplement|June 28, 2005
AT1-receptor blockers and ACE inhibitors: alternatives or partners?L M Ruilope
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 1, 1997
The kidney and cardiovascular riskL M Ruilope
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 1, 1995
Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathyL M Ruilope
Pageof 29